475207-59-1 Sorafenib tosylate AKSci J10732
 
 
Loading Please Wait...
  J10732    AKSci Reference Standard
Sorafenib tosylate
, >99% (HPLC), powder
 
4-methylbenzolsulfons




IDENTITY
CAS Number:475207-59-1
MDL Number:MFCD08235032
MF:C28H24ClF3N4O6S
MW:637.03
SPECIFICATIONS & PROPERTIES
Purity:>99% (HPLC), powder
Spectra:NMR, LCMS, HPLC
Physical Form:White crystalline powder
Melting Point:240-243°C
Long-Term Storage:Store at room temperature

BIOLOGICAL INFO
Solubility:DMSO: 127mg/mL; H2O: <1mg/mL; EtOH: <1mg/mL
Application(s):Inhibitor of several Tyrosine protein kinases (VEGFR and PDGFR) and Raf kinases (more avidly C-Raf t
Form:Tosylate

REVIEW

 Sorafenib is a novel bi-aryl urea compound that inhibits cell proliferation by targeting the ERK pathway and angiogenesis by targeting the receptor tyrosine kinases VEGFR-2 and PDGFR-β and their associated signaling cascades. Although sorafenib was initially developed as a Raf kinase inhibitor (IC50 = 6 nM), it has since been shown to have activity against many receptor tyrosine kinases involved in tumorigenesis and angiogenesis including FGFR-1, wt BRAF and V599E mutant BRAF, as well as members of the so-called split kinase family: VEGFR-2, VEGFR-3, PDGFR-β, c-KIT, and Flt3. However, sorafenib is not active against erbB1, erbB2, ERK-1, MEK-1, EGFR, HER-2, IGFR-1, c-MET, c-yes, PKB, PKA, cdk1/cyclinB, PKC, and pim-1. In cellular mechanistic assays, sorafenib decreased basal phosphorylation of the ERK pathway in melanoma, breast, colon, and pancreatic tumor cell lines.

REFERENCES
[1]M. Danielle Bareford, Margaret A. Park, Adly Yacoub, Hossein A. Hamed, Yong Tang, Nichola Cruickshanks, Patrick Eulitt, Nisan Hubbard, Gary Tye, Matthew E. Burow, Paul B. Fisher, Richard G. Moran, Kenneth P. Nephew, Steven Grant, and Paul Dent.:Sorafenib Enhances Pemetrexed Cytotoxicity through an Autophagy-Dependent Mechanism in Cancer Cells.Cancer Res., Jul 2011; 71: 4955 - 4967.
[2] Eulitt PJ, Park MA, Hossein H, Cruikshanks N, Yang C, Dmitriev IP, Yacoub A, Curiel DT, Fisher PB, Dent P.Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery.Cancer Biol Ther. 2011 Jan 12;10(12):1290-305. Epub 2010 Dec 15.
[3] M Danielle Bareford,1 Hossein A Hamed,1 Yong Tang,1 Nichola Cruickshanks,1 Matthew E Burow,7 Paul B Fisher,4,5 Richard G Moran,2 Kenneth P Nephew,6 Steven Grant,3,5 and Paul Dent.Sorafenib enhances pemetrexed cytotoxicity through an autophagy- dependent mechanism in cancer cellsPublished online 2011 October 1. doi: 10.4161/auto.7.10.17029

GHS

Pictograms

Signal Word
Warning

Hazard Statements
H315; H319; H335

Precautionary Statements
P261; P264; P271; P280; P302+P352; P304+P340; P305+P351+P338; P312; P321; P332+P313; P337+P313; P362; P403+P233; P405; P501


Current as of June 24, 2019

AKSci Reference Standards are high-purity, low-impurity compounds suitable for use as standards.


Download SDS

CATEGORIES

 APIs and Bioactives > Protein Kinase Inhibitors


PubChem